Study Title

Phase 1b/2 Open-label Trial of 225Ac-DOTATATE (RYZ101) Alone and in Combination with Pembrolizumab in Subjects with Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)-negative, Locally Advanced and Unresectable or Metastatic Breast Cancer Expressing Somatostatin Receptors (SSTRs) and Progressed After Antibody-drug Conjugates And/or Chemotherapy (TRACY-1)

Study Details

Description:

Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) alone and with pembrolizumab in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.

Sponsor:

RαyzeBio

Contacts:

RayzeBio Clinical Trials

clinicaltrials@rayzebio.com

(619) 657-0302

Government Study Link:

NCT06590857 - Click here to see study on

ClinicalTrials.gov

Drug Details

RYZ101
Isotope(s):
    ACTINIUM-225
    Radioisotope: Ac-225
    Theranostic Role: Therapeutic Agent & SPECT Imaging
    T1/2 (Half-Life): 9.9 Days
    Decay Mode: ALPHA, GAMMA
    Energy: 5.8-8.4 MeV
    Range: 47-85 micrometers
    Decay Daughters: Ra225, Fr221, At217, Bi213, 209, Po213, 209, TL209, 205
    Status: Clinical Trials Only
  • ACTINIUM-225
Target(s):
  • SSTR+
Chelator: DOTA

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468